Abstract
Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.
| Original language | English |
|---|---|
| Pages (from-to) | 1548-1556 |
| Number of pages | 9 |
| Journal | Experimental Hematology |
| Volume | 27 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1999 |
Fingerprint
Keywords
- Amifostine
- Nitrogen Mustard
- PBPC
- Purging
ASJC Scopus subject areas
- Cancer Research
- Cell Biology
- Genetics
- Hematology
- Oncology
- Transplantation
Cite this
Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard : Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. / Poloni, Antonella; Leoni, Pietro; Curzi, Laura; Cantori, Isabella; Mancini, Stefania; Montanari, Mauro; Masia, Maria Cristiana; Olivieri, Attilio.
In: Experimental Hematology, Vol. 27, No. 10, 10.1999, p. 1548-1556.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard
T2 - Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery
AU - Poloni, Antonella
AU - Leoni, Pietro
AU - Curzi, Laura
AU - Cantori, Isabella
AU - Mancini, Stefania
AU - Montanari, Mauro
AU - Masia, Maria Cristiana
AU - Olivieri, Attilio
PY - 1999/10
Y1 - 1999/10
N2 - Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.
AB - Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.
KW - Amifostine
KW - Nitrogen Mustard
KW - PBPC
KW - Purging
UR - http://www.scopus.com/inward/record.url?scp=0032872206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032872206&partnerID=8YFLogxK
U2 - 10.1016/S0301-472X(99)00086-7
DO - 10.1016/S0301-472X(99)00086-7
M3 - Article
C2 - 10517497
AN - SCOPUS:0032872206
VL - 27
SP - 1548
EP - 1556
JO - Experimental Hematology
JF - Experimental Hematology
SN - 0301-472X
IS - 10
ER -